Research Title: Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Sponsor: Regeneron Pharmaceuticals
Principal Investigator: Michael Jacobson, M.D.
Description: The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).
Start Date: February 2017
Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CRC; Halie Sklanka, CRC
Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084